Pharmacological Management of Sleep Maintenance Insomnia

First-Line Pharmacotherapy

The American Academy of Sleep Medicine recommends low-dose doxepin (3-6 mg) for sleep maintenance insomnia, reducing wake after sleep onset by 22-23 minutes, with a favorable safety profile through histamine H1 receptor antagonism at low doses 1, 2, 3, 4
Suvorexant (10-20 mg), an orexin receptor antagonist, is recommended for sleep maintenance insomnia, reducing wake time after sleep onset by 16-28 minutes and improving subjective total sleep time by 22.3-49.9 minutes, representing a different mechanism than traditional hypnotics 1, 2, 4
Eszopiclone (2-3 mg) is suggested for both sleep onset and sleep maintenance insomnia by the American Academy of Sleep Medicine 1
Zolpidem extended-release (10 mg, 5 mg in elderly) is recommended for sleep maintenance, with the extended-release formulation maintaining higher concentrations over more than 6 hours 1, 2
Temazepam (15 mg), an intermediate-acting benzodiazepine, is suggested for both sleep onset and maintenance insomnia 1, 4

In elderly patients, zolpidem must be reduced to 5 mg maximum due to increased risk of falls and cognitive impairment 2
Doxepin should be initiated at 3 mg and not exceed 6 mg in elderly patients 2

Trazodone is explicitly not recommended by the American Academy of Sleep Medicine for sleep maintenance insomnia due to significant fall risk and lack of efficacy 1, 2, 4
Over-the-counter antihistamines (diphenhydramine, etc.) are not recommended due to lack of efficacy data, safety concerns, and increased anticholinergic burden 1, 2, 5
Antipsychotics should not be used as first-line due to problematic metabolic side effects including weight gain and metabolic dysfunction 4, 5
Long-acting benzodiazepines (diazepam, clonazepam, lorazepam) carry increased risks without clear benefit, with half-lives longer than 24 hours leading to accumulation and impaired clearance in older patients and those with liver disease 5
Herbal supplements (valerian) and melatonin are not recommended due to insufficient evidence of efficacy 1, 5

All hypnotics should be prescribed at the lowest effective dose for the shortest period possible, typically less than 4 weeks for acute insomnia, with risks including daytime memory and psychomotor impairment, complex behaviors, depression, suicidal thoughts, and associations with dementia 1, 3, 5
If insomnia persists after 7-10 days of appropriate treatment, reevaluate for comorbid sleep disorders such as restless legs syndrome and obstructive sleep apnea 1, 4

Cognitive Behavioral Therapy for Insomnia (CBT-I) should be implemented alongside any pharmacotherapy as it has superior long-term efficacy compared to medications alone and is recommended as first-line treatment before considering medications 1, 2, 4

Do not use sedating agents without considering their specific effects on sleep maintenance versus sleep onset, as zaleplon and ramelteon are primarily for sleep onset, not maintenance 1
Do not combine multiple sedative medications, as this significantly increases risks including complex sleep behaviors, cognitive impairment, falls, and fractures, particularly in elderly patients 1
Do not continue pharmacotherapy long-term without periodic reassessment every 2-4 weeks to assess effectiveness, side effects, and plan for medication tapering 1, 2